ACMJ

Anatolian Current Medical Journal (ACMJ) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

EndNote Style
Index
Original Article
Duodenal IgE and mast cells changes in diabetes mellitus patients
Aims: To determine the differences in duodenal biopsies of diabetes mellitus (DM) patients and non-diabetic patients by investigating the numbers of immunoglobulin E (IgE) positive plasma cells, IgE positive mast cells, and eosinophils.
Methods: Patients diagnosed with chronic duodenitis and DM and those diagnosed only with chronic duodenitis within between 2010-2020 years were detected from the hospital information system. Paraffin blocks and hematoxylin-eosin-stained preparations of the patients’ duodenal biopsies were obtained from the hospital’s pathology archive. By performing IgE immunohistochemical staining for all blocks, the sections were evaluated through light microscopy.
Results: A total of 75 patients, 45 with DM and 30 non-diabetic patients with chronic duodenitis were included in the study. While IgE accumulation was prominently detected in the plasma cells and mast cells of DM patients’ duodenal tissue samples, no significant IgE accumulation was detected in the biopsies of non-diabetic patients with chronic duodenitis.
Conclusion: To date, the effectiveness of mast cells, IgE, and duodenal histological changes in DM have been proven, but our study is the first to detect the increase in mast cells and IgE in duodenal biopsies of DM patients. High IgE in the duodenum could support the relationship between DM and food allergy. We consider that higher IgE antibodies detected in diabetic patients’ duodenums will reveal promising novel results in elucidating DM pathophysiology and regulating the treatment modalities, and will shed light on future studies.


1. Rao JN, Wang JY. Regulation of gastrointestinal mucosalgrowth. San Rafael (CA): Morgan & Claypool Life Sciences;2010. Available from: https://www.ncbi.nlm.nih.gov/books/NBK54091/
2. Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM.Gastrointestinal complications of diabetes mellitus. World JDiabetes. 2013;4(3):51-63.
3. Zhong HJ, Yuan Y, Xie WR, Chen MH, He XX. Type 2 diabetesmellitus is associated with more serious small intestinal mucosalinjuries. PLoS One. 2016;11(9):e0162354.
4. Zhao M, Liao D, Zhao J. Diabetes-induced mechanophysiologicalchanges in the small intestine and colon. World J Diabetes.2017;8(6):249-269.
5. Kalaichelvi S. Prevalence of symptomatic peptic ulcer in diabetesmellitus patients at outpatient department of GovernmentMedical College and Hospital in and around Villupuram District.Int Arch Integrated Med. 2018;5(2)111-115.
6. Darra A, Singh V, Jena A, et al. Hyperglycemia is associated withduodenal dysbiosis and altered duodenal microenvironment.Scientific Rep. 2023;13(1):11038.
7. Lerkdumnernkit N, Sricharoenvej S, Lanlua P, et al. The effects ofearly diabetes on duodenal alterations in the rats. Int J Morphol.2022;40(2)389-395.
8. Maurer M, Taube C, Schröder NWJ, et al. Mast cells driveIgE-mediated disease but might be bystanders in many otherinflammatory and neoplastic conditions. J Allergy Clin Immunol.2019;144(4S):S19-S30.
9. Hoh RA, Joshi SA, Lee JY, et al. Origins and clonal convergenceof gastrointestinal IgE+ B cells in human peanut allergy. SciImmunol. 2020;5(45):eaay4209.
10. Sun P, Wen H, Liu X, Ma Y, Jang J, Yu C. Time trends in type 2diabetes mellitus incidence across the BRICS from 1990 to 2019:an age-period-cohort analysis. BMC Public Health. 2022;22(1):65.
11. Lega IC, Lipscombe LL. Review: diabetes, obesity, and cancer-pathophysiology and clinical implications. Endocr Rev.2020;41(1):bnz014.
12. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiologyof type 1 and type 2 diabetes mellitus: a 90-year perspective.Postgrad Med J. 2016;92(1084):63-69.
13. Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus:a review on current treatment approach and gene therapy aspotential intervention. Diabetes Metab Syndr. 2019;13(1):364-372.
14. Brunkwall L, Orho-Melander M. The gut microbiome as atarget for prevention and treatment of hyperglycaemia in type2 diabetes: from current human evidence to future possibilities.Diabetologia. 2017;60(6):943-951.
15. Frydrych LM, Bian G, O’Lone DE, Ward PA, Delano MJ.Obesity and type 2 diabetes mellitus drive immune dysfunction,infection development, and sepsis mortality. J Leukoc Biol.2018;104(3):525-534.
16. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolicdisease. Immunity. 2014;41(1):36-48.
17. Divoux A, Moutel S, Poitou C, et al. Mast cells in human adiposetissue: link with morbid obesity, inflammatory status, anddiabetes. J Clin Endocrinol Metab. 2012;97(9):E1677-E1685.
18. Liu J, Divoux A, Sun J, et al. Genetic deficiency andpharmacological stabilization of mast cells reduce diet-inducedobesity and diabetes in mice. Nat Med. 2009;15(8):940-945.
19. Wang Z, Zhang H, Shen XH, et al. Immunoglobulin E andmast cell proteases are potential risk factors of impaired fastingglucose and impaired glucose tolerance in humans. Ann Med.2013;45(3):220-229.
20. Divoux A, Moutel S, Poitou C, et al. Mast cells in human adiposetissue: link with morbid obesity, inflammatory status, anddiabetes. J Clin Endocrinol Metab. 2012;97(9):E1677-E1685.
21. Liu J, Divoux A, Sun J, et al. Genetic deficiency andpharmacological stabilization of mast cells reduce diet-inducedobesity and diabetes in mice. Nat Med. 2009;15(8):940-945.
22. Svensson J, Eising S, Mortensen HB, et al. High levels ofimmunoglobulin E and a continuous increase in immunoglobulinG and immunoglobulin M by age in children with newlydiagnosed type 1 diabetes. Hum Immunol. 2012;73(1):17-25.
23. Maier LM, Howson JM, Walker N, et al. Association of IL13 withtotal IgE: evidence against an inverse association of atopy anddiabetes. J Allergy Clin Immunol. 2006;117(6):1306-1313.
24. Caffarelli C, Romanini E, Caruana P, Street ME, de’ AngelisG. Clinical food hypersensitivity: the relevance of duodenalimmunoglobulin e-positive cells. Pediatr Res. 1998;44(4):485-490.
25. Andre F, Andre C, Descos L, Colin L, Cavagna S. Diagnosis of foodallergy by counting IgE-positive duodenal cells. Revue FrançaiseD’allergologie et D’immunologie Clinique. 1993;33(2):119-123.
26. Berczi L, Sebestyén A, Fekete B, Tamássy K, Kopper L. IgE-containing cells in gastric mucosa with and without Helicobacterpylori infection. Pathol Res Pract. 2000;196(12):831-834.
27. Concepción Zavaleta MJ, Gonzáles Yovera JG, Moreno MarrerosDM, et al. Diabetic gastroenteropathy: an underdiagnosedcomplication. World J Diabetes. 2021;12(6):794-809.
28. Zopf Y, Baenkler HW, Silbermann A, Hahn EG, Raithel M. Thedifferential diagnosis of food intolerance. Dtsch Arztebl Int.2009;106(21):359-370.
29. Willis FB, Susan P, Patch A. Prediabetes reduction from foodallergen elimination. Med Clin Case Rep. 2023;3(1):1-3.
30. Willis FB, Shanmugam R, Sullivan JH, Rodriguez JP, Mouton CP.Food allergen elimination for obesity reduction; a longitudinal,case-control trial (n= 94): 2295. Med Sci Sports Exercise.2022;54(9):671.
31. Hessner MJ, Wang X, Meyer L, et al. Involvement of eotaxin,eosinophils, and pancreatic predisposition in developmentof type 1 diabetes mellitus in the BioBreeding rat. J Immunol.2004;173(11):6993-7002.
Volume 6, Issue 1, 2024
Page : 1-5
_Footer